Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding
Policy brief
18 December 2020
| COVID-19: Critical preparedness, readiness and response
Overview
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This policy brief was developed by the WHO Access to COVID-19 Tools (ACT)Accelerator Ethics & Governance Working Group, to provide guidance for researchers, sponsors, regulators, research ethics committees, and policy-makers, on these and related issues.
Read more
WHO Team
ACT Accelerator Ethics & Governance Working Group,
Health Ethics & Governance (HEG),
WHO Expert Group on ethics and governance of infectious disease outbreaks and other emergencies,
WHO Headquarters (HQ)
Editors
WHO
Number of pages
6
Reference numbers
WHO Reference Number: WHO/2019-nCoV/Policy_Brief/EUD_placebo-controlled_vaccine_trials/2020.1
Copyright
